Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265121 | PMC |
| http://dx.doi.org/10.1001/jamanetworkopen.2024.23926 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.
Vaccine
December 2024
Optum Epidemiology, Boston, MA, USA.
Background: Limited data exists regarding the safety of the COVID-19 2023-2024 vaccine formulations and whether the safety profiles differ from the original formulations. We evaluated the association between the BNT162b2 XBB COVID-19 vaccine and the risk of 20 pre-specified adverse events of special interest (AESIs).
Methods: We identified commercially-insured individuals in the US age ≥ 6 months who received the BNT162b2 XBB COVID-19 vaccine between September 11, 2023 and January 15, 2024 within the Optum pre-adjudicated database.
Reemerging Infectious Diseases and Neuroimmunologic Complications.
Neurol Neuroimmunol Neuroinflamm
January 2025
Department of Neurology, University of Pennsylvania, Philadelphia.
During the past decade (and beyond), neurologists have become aware of the emergence, persistence, and consequences of some familiar and new infections affecting the nervous system. Even among the familiar CNS infections, such as herpes virus, polyoma virus/JC, influenza, arbovirus, and hepatitis, challenges remain in developing effective antiviral treatments and treatments of postinfection sequelae. With the changing environment and increased global travel, arthropod vectors that mediate zoonotic disease transmission have spread unfamiliar viruses such as West Nile virus, dengue, chikungunya, equine encephalitis, and Zika, among others.
View Article and Find Full Text PDFNeurological symptoms and complications of influenza in the elderly.
Neuro Endocrinol Lett
November 2024
Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic.
Background: An in-depth study of neurological symptoms and complications of influenza in elderly patients. This population group is more susceptible to complications of the disease and these complications are more likely to end in death.
Methods: A retrospective analysis of patient data was performed.
Article Synopsis
- The text discusses the importance of forecasting future health issues in the USA for effective planning and public awareness regarding disease and injury burdens.
- It describes the methodology for predicting life expectancy, cause-specific mortality, and disability-adjusted life-years (DALYs) from 2022 to 2050 using the Global Burden of Diseases framework.
- The forecasting includes various scenarios to assess the potential impacts of health risks and improvements across the country, focusing on demographic trends and health-related risk factors.
Phospholipid Scramblase 1 (PLSCR1) Regulates Interferon-Lambda Receptor 1 (IFN-λR1) and IFN-λ Signaling in Influenza A Virus (IAV) Infection.
bioRxiv
November 2024
Department of Molecular Microbiology and Immunology, Brown University, RI, USA.
Phospholipid scramblase 1 (PLSCR1) is an antiviral interferon-stimulated gene (ISG) that has several known anti-influenza functions such as interfering with viral nuclear import, regulating toll-like receptor (TLR) 9 and potentiating the expression of other ISGs. However, the exact mechanisms of anti-flu activity of PLSCR1 in relation to its expression compartment and enzymatic activity, and the molecular and cellular mechanisms involved have not been completely explored. Moreover, only limited animal models have been studied to delineate its role at the tissue level in influenza infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!